Intravascular red cell aggregation in children with heart disease.
Explore the source record for details and available documents.
SEARCH · PubMed Health
Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.
Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
One hundred and ninety-eight patients with congestive circulatory insufficiency were examined; 54 had stage IIA, 88 stage IIB, and 56 stage III of the disease. Blood viscosity, blood platelet and erythrocyte aggregation, fibrinogen disintegration products, and soluble fibrin were determined and the protamine sulfate test was performed. Statistically significant reduction of hematocrit, increase of erythrocyte aggregation, dysfunction of blood platelets, and increase in the content of products of fibrinogen and fibrin disintegration were revealed with progression of congestive circulatory insufficiency. These changes are evidence of disseminated intravascular coagulation in such patients and are important in prognostication.
Thrombotic microangiopathy (TMA) is a rare but devastating disorder; it involves small vessels and is characterized by intravascular thrombi of aggregated platelets leading to thrombocytopenia and variable degrees of organ ischemia and anemia, which is due to erythrocyte fragmentation in microcirculation. Childhood cases with predominant renal involvement are referred as the hemolytic uremic syndrome (HUS), and adults with major central neurological involvement are labeled as thrombotic thrombocytopenia purpura (TTP). Endothelial damage due to toxins and/or lack of defense against complement activation have a central role. Recent discovery of the von Willebrand Factor cleaving protease (ADAMTS 13) has offered new insight into the pathogenesis of TMA. TMA is also a well-recognized serious complication of renal transplantation. Clinical features of intravascular hemolysis are not always found. It may occur as de novo or recurrent and the majority of de novo cases are related to cyclosporin therapy. Viral infections, severe renal ischemia and acute vascular rejection are less frequent causes. Recurrence is negligible in diarrhea-associated HUS in childhood, but non-diarrheal HUS recurs in majority of adults following renal transplantation. Renal transplantation is contraindicated in familial/relapsing recurrent forms of HUS.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Rheologic properties of red blood cells and hemostasis were studied in patients with acquired autoimmune hemolytic anemia who received antilymphocytic globulin (ALG). Hypocoagulation changes attended by elevation of red blood cell aggregation activity were detected in the patients already at their admission to the hospital. After administration of ALG, growth of these shifts, characteristic of disseminated intravascular blood coagulation (DIC) syndrome, was noted. It was shown that erythrocytic thromboplastin and antiheparin factor action on blood coagulation, mainly at the expense of the young cell fraction, was responsible for disorders in hemostasis. Nevertheless, despite the presence of DIC syndrome, in the group of patients, who received ALG, no clinical signs of this state were recorded, that could be explained by the protective effect of red blood cell intensified capacity for aggregation leading to the improvement of blood coagulation parameters.
Improving hemocompatibility is of major interest in extracorporeal circulation (ECC). Changes in numbers and functions of the blood cells during ECC have been ascribed to the nonphysiologic materials of the circuit. In this study, commonly used priming fluids (banked blood, Ringer's lactated solution, gelatin solution and dextran 70 solution) have been investigated for their influence on numbers and functions of canine thrombocytes, leukocytes and erythrocytes. Infusion of banked blood and Ringer's lactated solution did not affect number and function of the thrombocytes, whereas the plasma expanders caused dramatic, but reversible decreases. Leukocyte numbers were also affected, but only gelatin resulted in a decrease of leukocyte function. No effect on erythrocyte numbers was observed. It is concluded that under these experimental circumstances some priming solutions cause acute intravascular aggregation. To obtain the optimal condition for studying the hemocompatibility of ECC, preferably Ringer's lactated solution should be used.
OBJECTIVE: Pentoxifylline has been used experimentally, and acetylsalicylic acid (ASA) has been used clinically to improve skin-flap survival. This study tested the efficacy of each drug in the pig random skin-flap model. METHOD: Six flaps were elevated on each hypopigmented pig. After sacrifice on the seventh postoperative day, percent flap survival was determined. Control data were obtained from eleven pigs. Six experimental subjects were treated with pentoxifylline (25 mg/kg/d); six with ASA (8 mg/kg/d); and twelve with a combination of pentoxifylline and ASA (six for 7 days and six for 14 days). RESULTS: The mean flap survival +/- SEM was: 58.0 +/- 4.3% for the pentoxifylline group; 50.3 +/- 3.4% for the ASA group; 56.8 +/- 2.7% and 55.2 +/- 3.4% for the 7-day and 14-day combination groups, respectively. There was no significant increase in flap survival with any of the experimental groups when compared to controls (49.6 +/- 1.8%). CONCLUSION: Red blood cell flexibility and platelet aggregation studies documented the expected intravascular drug effects, but did not correlate well with flap survival.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.